• Male

Prof. dr. J.D. Bos

Position:
Main activities: Patient care, Research, Teaching
Specialisation:
foto
Focus of research:
AMC themes: Infection & Immunity
Departments: Dermatology
Roekevisch E, Schram ME, Leeflang MMG, Brouwer MWD, Gerbens LAA, Bos JD, Spuls PI, Methotrexate versus azathioprine in patients with atopic dermatitis: two years follow-up data. J ALLERGY CLIN IMMUN 2017;-:- [PubMed]
Szegedi K, van Lier A, Res PC, Chielie S, Bos JD, Kezic S, Middelkamp-Hup MA, Luiten RM, House Dust Mite allergens Der f and Der p induce IL-31 production by blood derived T cells from Atopic Dermatitis patients. EXP DERMATOL 2017;ahead of print [PubMed]
Roekevisch E, Leeflang MMG, Schram ME, Campbell LE, Irwin McLean WH, Kezic S, Bos JD, Spuls PI, Middelkamp-Hup MA, Atopic dermatitis patients with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment. BRIT J DERMATOL 2016;-:- [PubMed]
Teulings HE, Ceylan E, Overkamp M, Vrijman C, Bos JD, Nijsten TE, Wolkerstorfer A, Luiten RM, van der Veen JPW, Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged ≥ 50 years. BRIT J DERMATOL 2016;175 (4):821-824 [PubMed]
D'Erme A Massimiliano, Bos JD. Atopic Dermatitis in: Katsambas A, Lotti T M., Dessinioti C, D'Erme A Massimiliano, editors. European Handbook of Dermatological Treatments (3rd ed.). Berlin Heidelberg: Springer-Verlag; 2015., p. 73-91
Kroon MW. Pigmented skin disorders: Evaluation and treatment. S.l.: s.n.; 2015. 184p. ISBN 978-90-9028861-1 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Luiten RM; copromotor(s): Wolkerstorfer A, van der Veen JPW)
Szegedi K, Lutter R, Res PC, Bos JD, Luiten RM, Kezic S, Middelkamp-Hup MA, Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J EUR ACAD DERMATOL 2015;29 (11):2136-2144 [PubMed]
Teulings HE. Melanoma versus vitiligo: Clinical aspects and implications for immunotherapy. S.l.: s.n.; 2015. 204p. ISBN 978-94-6182-586-5 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Luiten RM; copromotor(s): Bos JD, van der Veen JPW)
Vrijman C. Evaluation and treatment of vitiligo. S.l.: s.n.; 2015. 217p. ISBN 978-94-6182-543-8 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Luiten RM, Bos JD; copromotor(s): Wolkerstorfer A, van der Veen JPW)
Visser MJ. Susceptibility to hand eczema in high risk occupations: Contribution of genetic and environmental factors. s.l.: s.n.; 2014. 164p. ISBN 9789461824240 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, van Dijk FJH; copromotor(s): Kezić S, Verberk MM)
Visser MJ, Verberk MM, Campbell LE, McLean WHI, Calkoen F, Bakker JG , van Dijk FJH, Bos JD, Kezic S, Filaggrin loss-of-function mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study. CONTACT DERMATITIS 2014;70 (3):139-150 [PubMed]
Visser MJ, Verberk MM, van Dijk FJH, Bakker JG , Bos JD, Kezic S, Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. CONTACT DERMATITIS 2014;70 (1):44-55 [PubMed]
Kroon MW, Kemp EH, Wind BS, Krebbers G, Bos JD, Gawkrodger DJ, Wolkerstorfer A, van der Veen JPW, Luiten RM, Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. J EUR ACAD DERMATOL 2013;27 (9):1172-1175 [PubMed]
Kroon MW, Vrijman C, Chandeck C, Wind BS, Wolkerstorfer A, Luiten RM, Bos JD, Geskus RB, van Trotsenburg P, van der Veen JPW, High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. HORM RES PAEDIAT 2013;79 (3):137-144 [PubMed]
Teulings HE, Overkamp M, Ceylan E, Nieuweboer-Krobotova L, Bos JD, Nijsten T, Wolkerstorfer AW, Luiten RM, van der Veen JPW, Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. BRIT J DERMATOL 2013;168 (1):162-171 [PubMed]
van der Aar AMG, Picavet DI, Muller FJ, de Boer L, van Capel TMM, Zaat SAJ, Bos JD, Janssen H, George TC, Kapsenberg ML, van Ham SM, Teunissen MBM, de Jong EC, Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J INVEST DERMATOL 2013;133 (5):1240-1249 [PubMed]
Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JPW, Luiten RM, Provoking factors, including chemicals, in Dutch patients with vitiligo. BRIT J DERMATOL 2013;168 (5):1003-1011 [PubMed]
de Groot M, Picavet DI, van Kuijk AWR, Tak PP, Bos JD, de Rie MA, Teunissen MBM, A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin. DERMATOLOGY 2012;225 (4):298-303 [PubMed]
Kroon MW, Joore ICKW, Wind BS, Leloup MAC, Wolkerstorfer A, Luiten RM, Bos JD, Geskus RB, van der Veen JPW, Low yield of routine screening for thyroid dysfunction in asymptomatic patients with vitiligo. BRIT J DERMATOL 2012;166 (3):532-538 [PubMed]
Kroon MW, Wind BS, Meesters AA, Wolkerstorfer A, van der Veen JPW, Bos JD, van der Wal AC, Beek JF, Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J DERMATOL TREAT 2012;23 (5):339-344 [PubMed]
Lebre MC, Jonckheere CL, Kraan MC, van Kuijk AWR, Bos JD, de Rie M, Gerlag DM, Tak PP, Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. ARTHRITIS RES THER 2012;14 (5):R200 [PubMed]
Linthorst Homan MW. Clinical and patient reported outcomes in vitiligo. s.l.: s.n.; 2012. 139p. ISBN 9789461821522 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Sprangers MAG; copromotor(s): van der Veen JPW, de Korte J)
Linthorst Homan MW, Spuls PI, Nieuweboer-Krobotova L, de Korte J, Sprangers MAG, Bos JD, Wolkerstorfer A, van der Veen JPW, A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients. J EUR ACAD DERMATOL 2012;26 (6):690-695 [PubMed]
Peters MAD, van Drooge AM, Wolkerstorfer A, van Gemert MJC, van der Veen JPW, Bos JD, Beek JF, Double Pass 595?nm pulsed dye laser at a 6 minute interval for the treatment of port-wine stains is not more effective than single pass. LASER SURG MED 2012;44 (3):199-204 [PubMed]
Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI, Methotrexaat versus azathioprine bij ernstig atopisch eczeem. NED TIJDSCHR DERMATOL VENEREOL 2012;22 (3):176-179
Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI, Response to a randomized trial of methotrexate vs. azathioprine for severe atopic eczema: a critical appraisal. BRIT J DERMATOL 2012;166 (4):704-U27
Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J, EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. ALLERGY 2012;67 (1):99-106 [PubMed]
Szegedi K, Kremer AE, Kezic S, Teunissen MBM, Bos JD, Luiten RM, Res PC, Middelkamp-Hup MA, Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. EXP DERMATOL 2012;21 (6):431-436 [PubMed]
Wind BS, Meesters AA, Kroon MW, Beek JF, van der Veen JPW, van der Wal AC, Bos JD, Wolkerstorfer A, Formation of Fibrosis After Nonablative and Ablative Fractional Laser Therapy. DERMATOL SURG 2012;38 (3):437-442 [PubMed]
de Groot M. Innovative therapies and new targets in psoriasis. s.l.: s.n.; 2011. 156p. ISBN 9789490371760 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): de Rie MA, Teunissen MBM)
Jakasa I, Koster ES, Calkoen F, McLean WHI, Campbell LE, Bos JD, Verberk MM, Kezic S, Skin Barrier Function in Healthy Subjects and Patients with Atopic Dermatitis in Relation to Filaggrin Loss-of-Function Mutations. J INVEST DERMATOL 2011;131 (2):540-542 [PubMed]
Kroon MW, Wind BS, Beek JF, van der Veen JPW, Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A, Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled pilot study. J AM ACAD DERMATOL 2011;64 (3):516-523 [PubMed]
Lecluse LLA, Dowlatshahi EA, Limpens CEJM, de Rie MA, Bos JD, Spuls PI, Etanercept An Overview of Dermatologic Adverse Events. ARCH DERMATOL 2011;147 (1):79-94 [PubMed]
Meesters AA, Wind BS, Kroon MW, Wolkerstorfer A, van der Veen JPW, Nieuweboer-Krobotová L, van der Wal AC, Bos JD, Beek JF, Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J AM ACAD DERMATOL 2011;65 (6):1173-1179 [PubMed]
Schram ME. Atopic dermatitis: epidemiology & off-label therapy. s.l.: s.n.; 2011. 219p. ISBN 9789461820082 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Spuls PI, Leeflang MMG)
Schram ME, Leeflang MMG, den Ottolander JPS, Spuls PI, Bos JD, Validation and refinement of the Millennium Criteria for atopic dermatitis. J DERMATOL 2011;38 (9):850-858 [PubMed]
Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI, A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J ALLERGY CLIN IMMUN 2011;128 (2):353-359 [PubMed]
Tjin EPM, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KLMC, van der Horst CMAM, Bos JD, Nieweg OE, Kroon BBR, Haanen JBAG, Melief CJM, Vyth-Dreese FA, Luiten RM, T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. CLIN CANCER RES 2011;17 (17):5736-5747 [PubMed]
van den Boorn JG, Picavet DI, van Swieten PF, van Veen HA, Konijnenberg D, van Veelen PA, van Capel T, Jong ECd, Reits EA, Drijfhout JW, Bos JD, Melief CJM, Luiten RM, Skin-Depigmenting Agent Monobenzone Induces Potent T-Cell Autoimmunity toward Pigmented Cells by Tyrosinase Haptenation and Melanosome Autophagy. J INVEST DERMATOL 2011;131 (6):1240-1251 [PubMed]
van der Heijden JP, de Keizer NF, Bos JD, Spuls PI, Witkamp L, Teledermatology applied following patient selection by general practitioners in daily practice improves efficiency and quality of care at lower cost. BRIT J DERMATOL 2011;165 (5):1058-1065 [PubMed]
Vrijman C, van Drooge AM, Limpens J, Bos JD, van der Veen JPW, Spuls PI, Wolkerstorfer A, Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. BRIT J DERMATOL 2011;165 (5):934-942 [PubMed]
Wind BS. Photo- and laser therapy in pigment disorders. s.l.: s.n.; 2011. 113p. ISBN 9789490371845 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): van der Veen JPW, Wolkerstorfer A)
Wind BS, Meesters AA, Kroon MW, Beek JF, van der Veen JPW, Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A, Punchgraft testing in vitiligo; effects of UVA, NB-UVB and 632.8 nm Helium-Neon laser on the outcome. J EUR ACAD DERMATOL 2011;25 (10):1236-1237 [PubMed]
Bos JD, Brenninkmeijer EEA, Schram ME, Middelkamp-Hup MA, Spuls PI, Smitt JHS, Atopic eczema or atopiform dermatitis. EXP DERMATOL 2010;19 (4):325-331 [PubMed]
Brenninkmeijer EEA, Spuls PI, Lindeboom R, van der Wal AC, Bos JD, Wolkerstorfer A, Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. BRIT J DERMATOL 2010;163 (4):823-831 [PubMed]
de Groot M, Teunissen MBM, Picavet DI, de Rie MA, Bos JD, Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. EXP DERMATOL 2010;19 (8):754-756 [PubMed]
Kok MR, Vos K, Bos JD, Tak PP, Remission of Incapacitating Acute Cutaneous Lupus Erythematosus in a Patient With Systemic Lupus Erythematosus by B Cell-Depletive Therapy. JCR-J CLIN RHEUMATOL 2010;16 (7):345 [PubMed]
Lecluse LLA. Psoriasis: implications of biologics. s.l.: s.n.; 2010. 209p. ISBN 9789490122805 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Spuls PI, de Rie MA)
Lecluse LLA, Driessen RJB, Spuls PI, de Jong EMGJ, Stapel SO, van Doorn MBA, Bos JD, Wolbink GJ, Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis. ARCH DERMATOL 2010;146 (2):127-132 [PubMed]
Relyveld GN, Westerhof W, Woudenberg J, Kingswijk M, Langenberg M, Vandenbroucke-Grauls CM, Bos JD, Savelkoul PHM, Progressive Macular Hypomelanosis Is Associated with a Putative Propionibacterium Species. J INVEST DERMATOL 2010;130 (4):1182-1184 [PubMed]
Res PCM, Piskin G, de Boer OJ, van der Loos CM, Teeling P, Bos JD, Teunissen MBM, Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis. PLOS ONE 2010;5 (11):e14108 [PubMed]
Schram ME, Tedja AM, Spijker R, Bos JD, Williams HC, Spuls PI, Is there a rural/urban gradient in the prevalence of eczema? A systematic review. BRIT J DERMATOL 2010;162 (5):964-973 [PubMed]
Spuls PI, Lecluse LLA, Poulsen MLNF, Bos JD, Stern RS, Nijsten T, How Good Are Clinical Severity and Outcome Measures for Psoriasis?: Quantitative Evaluation in a Systematic Review. J INVEST DERMATOL 2010;130 (4):933-943 [PubMed]
van den Boorn JG. Vitiligo pathogenesis and immunotherapy of melanoma. s.l.: s.n.; 2010. 182p. ISBN 9789090371227 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Melief CJM; copromotor(s): Luiten RM)
van den Boorn JG, Konijnenberg D, Tjin EPM, Picavet DI, Meeuwenoord NJ, Filippov DV, van der Veen JPW, Bos JD, Melief CJM, Luiten RM, Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG. PLOS ONE 2010;5 (5):e10626 [PubMed]
van der Aar AMG. Functional specialization of human skin dendritic cell subsets in immunity to different slasses of pathogens. s.l.: s.n.; 2010. 160p. ISBN 9789490371104 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Kapsenberg ML; copromotor(s): Teunissen MBM, de Jong EC)
van der Heijden JP, de Keizer NF, Voorbraak FP, Witkamp L, Bos JD, Spuls PI, A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists. J TELEMED TELECARE 2010;16 (8):447-453 [PubMed]
van der Heijden JP, Spuls PI, Voorbraak FP, de Keizer NF, Witkamp L, Bos JD, Tertiary Teledermatology: A Systematic Review. TELEMED J E-HEALTH 2010;16 (1):56-62 [PubMed]
Wind BS, Kroon MW, Beek JF, van der Veen JPW, Nieuweboer-Krobotová L, Meesters AA, Bos JD, Wolkerstorfer A, Home vs. outpatient narrowband ultraviolet B therapy for the treatment of nonsegmental vitiligo: a retrospective questionnaire study. BRIT J DERMATOL 2010;162 (5):1142-1144 [PubMed]
Wind BS, Kroon MW, Meesters AA, Beek JF, van der Veen JPW, Nieuweboer-Krobotová L, Bos JD, Wolkerstorfer A, Non-Ablative 1,550 nm Fractional Laser Therapy Versus Triple Topical Therapy for the Treatment of Melasma: A Randomized Controlled Split-Face Study. LASER SURG MED 2010;42 (7):607-612 [PubMed]
Bos JD, Les origines de l'atopie, de la dermatite atopique et de la dermatite atopiforme: Plus de questions que de réponses.. KERATIN 2009;16:12-17
Bos JD, Luiten RM, Skin immune system. CANCER TREAT RES 2009;146:45-62 [PubMed]
Bos JD, Schram ME, Mekkes JR, Dermatologists are essential for quality of care in the general practice of medicine. ACTAS DERMOSIFILIOGR 2009;100 (Suppl. 1):101-105 [PubMed]
Brenninkmeijer EEA. Atopic and atopiform dermatitis. s.l.: s.n.; 2009. 159p. ISBN 9789090240893 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Spuls PI, Sillevis Smitt JH)
Brenninkmeijer EEA, Legierse CM, Sillevis Smitt JH, Last BF, Grootenhuis MA, Bos JD, The Course of Life of Patients with Childhood Atopic Dermatitis. PEDIATR DERMATOL 2009;26 (1):14-22 [PubMed]
de Groot M, de Rie MA, Bos JD, DRESS syndrome caused by efalizumab: comment. CLIN EXP DERMATOL 2009;34 (3):414 [PubMed]
Faber WR, Bos JD, Hulsebosch HJ, Rudi Harold Cormane (1925-1987): a fabulous researcher and clinician. CLIN DERMATOL 2009;27 (2):237-239 [PubMed]
Kammeyer A, Bos JD, Teunissen MBM, Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. EXP DERMATOL 2009;18 (1):44-49 [PubMed]
Kezic S, Kammeyer A, Calkoen F, Fluhr JW, Bos JD, Natural moisturizing factor components in the stratum corneum as biomarkers of filaggrin genotype: evaluation of minimally invasive methods. BRIT J DERMATOL 2009;161 (5):1098-1104 [PubMed]
Lecluse LLA, de Groot M, Bos JD, Spuls PI, Experience with biologics for psoriasis in daily practice: switching is worth a try. BRIT J DERMATOL 2009;161 (4):948-951 [PubMed]
Lecluse LLA, Tutein Nolthenius JLE, Bos JD, Spuls PI, Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. BRIT J DERMATOL 2009;160 (6):1340-1343 [PubMed]
Linthorst Homan MW, Spuls PI, de Korte J, Bos JD, Sprangers MA, van der Veen JPW, The burden of vitiligo: patient characteristics associated with quality of life. J AM ACAD DERMATOL 2009;61 (3):411-420 [PubMed]
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B, European S3-guidelines on the systemic treatment of psoriasis vulgaris. J EUR ACAD DERMATOL 2009;23 (Suppl. 2):1-70 [PubMed]
Relyveld GN. Progressive macular hypomelanosis (PMH) teatable but often misdiagnosed. s.l.: s.n.; 2009. 131p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Westerhof W, Menke HE)
van den Boorn JG, Konijnenberg D, Dellemijn TAM, van der Veen JPW, Bos JD, Melief CJM, Vyth-Dreese FA, Luiten RM, Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients. J INVEST DERMATOL 2009;129 (9):2220-2232 [PubMed]
Bos JD, Spuls PI, Topical treatments in psoriasis: today and tomorrow. CLIN DERMATOL 2008;26 (5):432-437 [PubMed]
Brenninkmeijer EEA, Schram ME, Leeflang MMG, Bos JD, Spuls PI, Diagnostic criteria for atopic dermatitis: a systematic review. BRIT J DERMATOL 2008;158 (4):754-765 [PubMed]
Brenninkmeijer EEA, Spuls PI, Legierse CM, Lindeboom R, Sillevis Smitt JH, Bos JD, Clinical differences between atopic and atopiform dermatitis. J AM ACAD DERMATOL 2008;58 (3):407-414 [PubMed]
Lebre MC, van Capel TMM, Bos JD, Knol EF, Kapsenberg ML, de Jong EC, Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J ALLERGY CLIN IMMUN 2008;122 (5):969-976 [PubMed]
Lecluse LLA, Piskin G, Bos JD, The use of patch tests in determining hypersensitivity to etanercept and infliximab. ARCH DERMATOL 2008;144 (8):1070-1; author reply 1071-2 [PubMed]
Lecluse LLA, Piskin G, Mekkes JR, Bos JD, de Rie MA, Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. BRIT J DERMATOL 2008;159 (3):527-536 [PubMed]
Linthorst Homan MW, de Korte J, Grootenhuis MA, Bos JD, Sprangers MAG, van der Veen JPW, Impact of childhood vitiligo on adult life. BRIT J DERMATOL 2008;159 (4):915-920 [PubMed]
Linthorst Homan MW, Sprangers MAG, de Korte J, Bos JD, van der Veen JPW, Characteristics of patients with universal vitiligo and health-related quality of life. ARCH DERMATOL 2008;144 (8):1062-1064 [PubMed]
Mekkes JR, Bos JD, Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. BRIT J DERMATOL 2008;158 (2):370-374 [PubMed]
Middelkamp-Hup MA, Bos JD, González S, Westerhof W, Regulation and modulation of skin melanogenesis. EXPERT REV DERMATOL 2008;3 (2):176-186
Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, Brenninkmeijer EEA, Smith C, Berth-Jones J, Ruzicka T, Sharpe G, Taieb A [Contributors: de Raeve L, Grønhøj-Larsen C, Remitz A, Turjanmaa K, Perrot JL, Boralevi F, Dubertret L, Lahfa M, Misery L, de Prost Y, Bodemer C, Stadler JF, Barbarot S, Plantin P, Schoenlaub P, Lorette G, Khallouf R, Beylot C, Bruckner-Tuderman L, Wollenberg A, Kamann S, Kapp A, Fartasch M, Fölster-Holst R, Bieber T, Ring J, Dobozy A, Kemény L, Murphy G, Barry J, Bourke J, Valdmane N, Blaszczyk M, Wolska H, Bos J, Carralero L, Carrera C, Martínez C, Rodríguez Pichardo A, de Frutos O, Sánchez-Largo Uceda E, Waite A, Green A, Friedmann P, Finlay A, Griffiths C]] , A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. BRIT J DERMATOL 2008;159 (4):942-951 [PubMed]
Relyveld GN, Dingemans KP, Menke HE, Bos JD, Westerhof W, Ultrastructural findings in progressive macular hypomelanosis indicate decreased melanin production. J EUR ACAD DERMATOL 2008;22 (5):568-574 [PubMed]
Bos JD, Psoriasis, innate immunity, and gene pools. J AM ACAD DERMATOL 2007;56 (3):468-471 [PubMed]
de Groot M, Teunissen MBM, Ortonne JP, Lambert JR, Naeyaert JM, Picavet DI, Arreaza MG, Simon JS, Kraan M, Bos JD, de Rie MA, Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. ARCH DERMATOL RES 2007;299 (7):305-313 [PubMed]
Jakasa I, Verberk MM, Esposito M, Bos JD, Kezic S, Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J INVEST DERMATOL 2007;127 (1):129-134 [PubMed]
Middelkamp-Hup MA. Detection, modulation and impact of skin pigmention. s.l.: s.n.; 2007. 192p. ISBN 9789090215204 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Westerhof W, Gonzalez S)
Middelkamp-Hup MA, Bos JD, Rius-Diaz F, Gonzalez S, Westerhof W, Treatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo-controlled study. J EUR ACAD DERMATOL 2007;21 (7):942-950 [PubMed]
Opmeer BC, Heydendael VMR, deBorgie CAJM, Spuis PI, Bossuyt PMM, Bos JD, de Rie MA, Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J CLIN EPIDEMIOL 2007;60 (7):696-703 [PubMed]
Reitamo S, Ortonne JP, Sand C, Bos J, Cambazard F, Bieber T, Gronhoj-Larsen C, Rustin M, Folster-Holst R, Schuttelaar M, Long-term treatment with 0.1% tacrolimus ointment in adults with atopic dermatitis: Results of a two-year, multicentre, non-comparative study. ACTA DERM-VENEREOL 2007;87 (5):406-412 [PubMed]
Teunissen MBM, Piskin G, Res PCJM, de Groot M, Picavet DI, de Rie MA, Bos JD, State of the art in the immunopathogenesis of psoriasis. GIORN ITAL DERMAT V 2007;142:229-242
Timar KK, Dallos A, Kiss M, Husz S, Bos JD, Asghar SS, Expression of terminal complement components by human keratinocytes. MOL IMMUNOL 2007;44 (10):2578-2586 [PubMed]
Timar KK, Junnikkala S, Dallos A, Jarva H, Bhuiyan ZA, Meri S, Bos JD, Asghar SS, Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. MOL IMMUNOL 2007;44 (11):2943-2949 [PubMed]
van der Aar AMG, Sylva-Steenland RMR, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MBM, Cutting edge: Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J IMMUNOL 2007;178 (4):1986-1990 [PubMed]
van der Meij N, Keur I, van Lienden KP, Scheepstra CG, Bos JD, Nefrogene systemische fibrose, mogelijk veroorzaakt door gadoliniumhoudend contrastmiddel. NED TIJDSCHR GENEESKD 2007;151 (52):2898-2903 [PubMed]
van Leent EJM, de Vries HJC, Ebelin ME, Burtin P, Scott G, Bos JD, Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel (R)) for up to 1 year. J DERMATOL TREAT 2007;18 (1):19-22 [PubMed]
Bos JD. Atopic versus atopiform dermatitis in: 15th Congress of the European academy of dermathology and venereology, Rhodes, Greece, October4-8, 2006. S.l.: Medimond S.r.l.; 2006., p. 29-34
Bos JD, 'Atopiform dermatitis' or 'atopic eczema'. FUTURE DRUGS 2006;1 (5):627-629
Bos JD, de Korte J, Effects of etanercept on quality of life, fatigue, and depression in psoriasis. LANCET 2006;367 (9504):6-7 [PubMed]
de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD, Initial experience with routine administration of etanercept in psoriasis. BRIT J DERMATOL 2006;155 (4):808-814 [PubMed]
de Korte J. Quality of life and quality of care in psoriasis. S.l.: s.n.; 2006. 133p. ISBN 90-9020253-6 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Sprangers MAG; copromotor(s): )
de Vries HJC, van Marle J, Teunissen MBM, Picavet D, Zorgdrager F, Bos JD, Weel J, Cornelissen M, De rol van humaan herpesvirus type 7(hhv-7) bij lichen planus. NED TIJDSCHR DERMATOL VENEREOL 2006;16 (dec):424-427
de Vries HJC, van Marle J, Teunissen MBM, Picavet D, Zorgdrager F, Bos JD, Weel J, Cornelissen M, Lichen planus is associated with human herpesvirus type 7 replication and infiltration of plasmacytoid dendritic cells. BRIT J DERMATOL 2006;154 (2):361-364 [PubMed]
Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA, CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. BRIT J DERMATOL 2006;155 (1):170-181 [PubMed]
Jakasa I. Dermal absorption of chemicals through normal and compromised skin. S.l.: s.n.; 2006. 166p. ISBN 9064646414 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): van Dijk FJH, Bos JD; copromotor(s): Verberk MM)
Jakasa I, de Jongh CM, Verberk MM, Bos JD, Kezić S, Percutaneous penetration of sodium lauryl sulphate is increased in uninvolved skin of patients with atopic dermatitis compared with control subjects. BRIT J DERMATOL 2006;155 (1):104-109 [PubMed]
Leonardi CL, Papp KA, Bos JD, Practical guidelines for the long-term treatment of psoriasis with efalizumab. J AM ACAD DERMATOL 2006;54 (4 Suppl. S):S153
Meijs MM, Hoekzema R, Bos JD, Subcorneale pustuleuze dermatose: ziekte van Sneddon-Wilkinson, IgA-pemphigus of psoriasis pustulosa?. NED TIJDSCHR DERMATOL VENEREOL 2006;16 (dec):441-444
Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA, Long-term management of plaque psoriasis with continuous efalizumab therapy. J AM ACAD DERMATOL 2006;54 (4 Suppl 1):S182-S188 [PubMed]
Piskin G, Meijs MM, van der Ham R, Bos JD, Glove allergy due to 1,3-diphenylguanidine. CONTACT DERMATITIS 2006;54 (1):61-62 [PubMed]
Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM, In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J IMMUNOL 2006;176 (3):1908-1915 [PubMed]
Relyveld GN, Kingswijk MM, Reitsma JB, Menke HE, Bos JD, Westerhof W, Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J AM ACAD DERMATOL 2006;55 (5):836-843 [PubMed]
Taïeb A, Hanifin J, Cooper K, Bos JD, Imokawa G, David TJ, Ring J, Gelmetti C, Kapp A, Furue M, de Prost Y, Darsow U, Werfel T, Atherton D, Oranje AP, Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J ALLERGY CLIN IMMUN 2006;117 (2):378-390 [PubMed]
Timár KK. Human keratinocytes: production of complement and chemokines. S.l.: s.n.; 2006. 151p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Asghar SS)
Timár KK, Pasch MC, van den Bosch NHA, Jarva H, Junnikkala S, Meri S, Bos JD, Asghar SS, Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. MOL IMMUNOL 2006;43 (4):317-325 [PubMed]
van der Meij N, Mekkes JR, de Wit FS, Leguit RJ, Bos JD, Lineaire IgA-dermatose, zowel klinisch als immunologisch een heterogene blaarziekte. NED TIJDSCHR DERMATOL VENEREOL 2006;16 (dec):438-440
Boehncke WH, Schön MP, Girolomoni G, Giromolomi G, Griffiths C, Bos JD, Thestrup-Pedersen K, Cavani A, Nestle F, Bonish BK, Campbell JJ, Brakebusch C, Nickoloff B, Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?. EXP DERMATOL 2005;14 (1):70-80 [PubMed]
Bos JD. A history of immunodermatology in: Bos JD, editors. Skin immune system. Cutaneous immunology and clinical immunodermatology. Boca Raton, Florida: CRC Press; 2005., p. 13-17
Bos JD, editor, Skin immune system. Cutaneous immunology and clinical immunodermatology. Boca Raton, Florida: CRC Press; 2005. -p. ISBN 0-8493-1959-5
Bos JD, editor, Skin immune system : Cutaneous immunology and clinical immunodermatology. Third edition. Boca Raton/New York: CRC Press; 2005. -p. ISBN 0 8493 1959 5
Bos JD. Skin immunity system (SIS) in: Bos JD, editors. Skin immune system. Cutaneous immunology and clinical immunodermatology. Boca Raton, Florida: CRC Press; 2005., p. 3-11
Bos JD, de Rie MA. Lupus erythematosus in: Bos JD, editors. Skin immune system. Cutaneous immunology and clinical immunodermatology. Boca Raton, Florida: CRC Press; 2005., p. 545-552
Bos JD, de Rie MA, Teunissen MBM, Piskin G, Psoriasis: dysregulation of innate immunity. BRIT J DERMATOL 2005;152 (6):1098-1107 [PubMed]
Caron-Schreinemachers ALDB, Kingswijk MM, Bos JD, Westerhof W, UVB 311 nm tolerance of vitiligo skin increases with skin photo type. ACTA DERM-VENEREOL 2005;85 (1):24-26 [PubMed]
de Groot M, de Rie MA, Bos JD, Dermatitis during efalizumab treatment in a patient with psoriasis vulgaris. BRIT J DERMATOL 2005;153 (4):843-845 [PubMed]
de Korte J, van Onselen J, Kownacki S, Sprangers MAG, Bos JD, Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J EUR ACAD DERMATOL 2005;19 (1):35-41 [PubMed]
de Rie MA, Bos JD. Biologicals for the treatment of immune-mediate skin disease in: Bos JD, editors. Skin immune system. Cutaneous immunology and clinical immunodermatology. Boca Raton, Florida: CRC Press; 2005., p. 789-804
de Rie MA, Bos JD. Photo(chemo)therapeutic modulation of the skin immune system in: Bos JD, editor. Skin immune system : Cutaneous immunology and clinical immunodermatology. Third edition. Boca Raton/New York: CRC Press; 2005., p. 771-788
Goedkoop AY. Effects of biological response modifiers in psoriasis and psoriatic arthritis. S.l.: s.n.; 2005. 172p. ISBN 90-9019312-X [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Tak PP; copromotor(s): de Rie MA, Teunissen MBM)
Goedkoop AY, de Rie MA, Teunissen MBM, Picavet DI, van der Hall PO, Bos JD, Tak PP, Kraan MC, Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. ARCH DERMATOL RES 2005;297 (2):51-59 [PubMed]
Jensema AJ, Bos JD, Unilaterale segmentale M. Darier. NED TIJDSCHR DERMATOL VENEREOL 2005;15 (aug):281-283
Piskin G, Bos JD, Teunissen MBM, Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. ARCH DERMATOL RES 2005;296 (7):339-342 [PubMed]
Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Fölster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C, A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. BRIT J DERMATOL 2005;152 (6):1282-1289 [PubMed]
Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K, The role of topical calcineurin inhibitors in atopic dermatitis. BRIT J DERMATOL 2004;151 (Suppl. 70):3-27 [PubMed]
Bos JD, De dermatoloog. NED TIJDSCHR GENEESKD : STUDENTENED 2004;7 (1):10-11
Bos JD, Proliferating prevalence of concepts and controversies in atopic eczema. J COSMET DERMATOL 2004;3 (4):243-244 [PubMed]
Bos JD, editor, Skin immune system. Cutaneous immunology and clinical immunodermatology. Boca Raton, Florida: CRC Press; 2004. -p. ISBN 0-8493-1959-5
Bos JD, The atopic epidemic and the humidity hypothesis. J COSMET DERMATOL 2004;3 (4):245 [PubMed]
de Korte J, Sprangers MA, Mombers FM, Bos JD, Quality of life in patients with psoriasis: A systematic literature review. J INVEST DERM SYMP P 2004;9 (2):140-147 [PubMed]
de Rie MA, Bos JD, New biological therapies for the treatment of psoriasis. GIORN ITAL DERMAT V 2004;139:3-13
de Rie MA, Bos JD, Ontwikkelingen van 'biologicals" voor de behandeling van psoriasis. NED TIJDSCHR DERMATOL VENEREOL 2004;14 (6):198-200
de Rie MA, Goedkoop AY, Bos JD, Overview of psoriasis. DERMATOL THER 2004;17 (5):341-349 [PubMed]
Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AWR, Tak PP, Bos JD, Teunissen MBM, Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. ARCH DERMATOL RES 2004;295 (11):465-473 [PubMed]
Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MBM, Bos JD, Tak PP, Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. ARTHRITIS RES THER 2004;6 (4):R326-R334 [PubMed]
Goedkoop AY, Kraan MC, Tak PP, Bos JD, de Rie MA, Picavet HSJ, Teunissen MBM, In vitro studies met biologicals in psoriasis. NED TIJDSCHR DERMATOL VENEREOL 2004;14 (juni):202-204
Goedkoop AY, Kraan MC, Teunissen MBM, Picavet DI, de Rie MA, Bos JD, Tak PP, Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. ANN RHEUM DIS 2004;63 (7):769-773 [PubMed]
Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA, The burden of psoriasis is not determined by disease severity only. J INVEST DERM SYMP P 2004;9 (2):131-135 [PubMed]
Heydendael VMR. Methotrexate versus cyclosporine in chronic plaque psoriasis. S.l.: s.n.; 2004. 159p. ISBN 90-9017726-4 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Bossuyt PMM; copromotor(s): de Rie MA, Spuls PI)
Heydendael VMR, Spuls PI, Bossuyt PMM, Bos JD, de Rie MA, Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. ARCH DERMATOL 2004;140 (10):1289-1290 [PubMed]
Heydendael VMR, Spuls PI, Opmeer BC, de Borgie CAJM, Reitsma JB, Goldschmidt WFM, Bossuyt PMM, Bos JD, de Rie MA, Methotrexaat en ciclosporine bij de behandeling van psoriasis. NED TIJDSCHR DERMATOL VENEREOL 2004;14 (juni):204-ev
Kammeyer A, Garssen J, Sleijffers A, van Loveren H, Eggelte TA, Bos JD, Teunissen MBM, Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. PHOTOCHEM PHOTOBIOL 2004;80 (1):72-77 [PubMed]
Luger TA, Lahfa M, Fölster-Holst R, Gulliver WP, Allen R, Molloy S, Barbier N, Paul C, Bos JD, Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J DERMATOL TREAT 2004;15 (3):169-178 [PubMed]
Mekkes JR, Loots MA, van der Wal AC, Bos JD, Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J AM ACAD DERMATOL 2004;50 (1):104-107 [PubMed]
Opmeer BC, Heydendael VMR, de Borgie CAJM, Spuls PI, Bossuyt PMM, Bos JD, de Rie MA, Costs of treatment in patients with moderate to severe plaque psoriasis - Economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. ARCH DERMATOL 2004;140 (6):685-690 [PubMed]
Pasch MC, Timár KK, van Meurs M, Heydendael VMR, Bos JD, Laman JD, Asghar SS, In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J PATHOL 2004;203 (3):839-848 [PubMed]
Piskin G. Effects of therapies on cytokine patterns in psoriasis. S.l.: s.n.; 2004. 195p. ISBN 90-9018242-X [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Teunissen MBM)
Piskin G, Sylva-Steenland MR, Bos JD, Teunissen MBM, Effect van behandeling met UVB op psoriasis. NED TIJDSCHR DERMATOL VENEREOL 2004;14 (6):200-201
Piskin G, Sylva-Steenland RMR, Bos JD, Teunissen MBM, T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. ARCH DERMATOL RES 2004;295 (12):509-516 [PubMed]
Piskin G, Tursen U, Sylva-Steenland RMR, Bos JD, Teunissen MBM, Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23. EXP DERMATOL 2004;13 (12):764-772 [PubMed]
Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, Moss C, Dobozy A, Palatsi R, 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. BRIT J DERMATOL 2004;150 (3):554-562 [PubMed]
Spuls PI, Bos JD, Rudikoff D, Smallpox: What the dermatologist should know. SKINMED 2004;3 (4):197-208 [PubMed]
Spuls PI, Witkamp L, Bossuyt PMM, Bos JD, The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. ARCH DERMATOL 2004;140 (3):338-344 [PubMed]
Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, de La Brassinne M, Ferrandiz C, Griffiths C, Katsambas A, Kragballe K, Lynde C, Menter A, Ortonne JP, Papp K, Prinz J, Rzany B, Ronnevig J, Saurat JH, Stahle M, Stengel FM, van de Kerkhof P, Voorhees J, Biological therapies in the systemic management of psoriasis: International Consensus Conference. BRIT J DERMATOL 2004;151 (Suppl. 69):3-17 [PubMed]
Bos JD. Current treatment of atopic dermatitis in: Ruzicka T, Reitamo S, editors. Tacrolimus ointment: a topical immunomodulator for atopic dermatitis. Berlin: Springer; 2003., p. 63-77
Bos JD, Non-steroidal topical immunomodulators provide skin-selective, self-limiting treatment in atopic dermatitis. EUR J DERMATOL 2003;13 (5):455-461 [PubMed]
Broeshart JH, Kammeyer A, Bos JD, Europese standaard over kleding en bescherming tegen ultraviolette straling. NED TIJDSCHR GENEESKD 2003;147 (45):2215-`2218 [PubMed]
de Korte J, Bos JD, Effects of inflammatory arthritis on quality of life in patients with psoriasis - In reply. ARCH DERMATOL 2003;139 (12):1655-1656
de Rie MA, Bos JD. Cyclic Immunosuppressive Drugs (Ch 14) in: Textbook of Psoriasis (2nd ed.). Oxford: Blackwell; 2003., p. 275-292
de Rie MA, Bos JD. Novel Immunotherapies (Ch 15) in: Textbook of Psoriasis. Oxford: Blackwell; 2003., p. 293-310
de Rie MA, Enomoto DNH, de Vries HJC, Bos JD, Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. DERMATOLOGY 2003;207 (3):298-301 [PubMed]
Eminović N, Witkamp L, Ravelli ACJ, Bos JD, van den Akker TW, Bousema MT, Henquet CJM, Koopman RJJ, Zeegelaar JE, Wyatt JC, Potential effect of patient-assisted teledermatology on outpatient referral rates. J TELEMED TELECARE 2003;9 (6):321-327 [PubMed]
Heydendael VMR, Spuls PI, Opmeer BC, de Borgie CAJM, Reitsma JB, Goldschmidt WFM, Bossuyt PMM, Bos JD, de Rie MA, Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. NEW ENGL J MED 2003;349 (7):658-665 [PubMed]
Kozel MMA, Bossuyt PMM, Mekkes JR, Bos JD, Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J AM ACAD DERMATOL 2003;48 (3):409-416 [PubMed]
Lebre MCGM. Initiation and regulation of specific immune responses by keratinocytes and dendritic cells. Role of cytokines and chemokines linking innate and specific immunity. S.l.: s.n.; 2003. 168p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Kapsenberg ML, Bos JD; copromotor(s): de Jong EC)
Mekkes JR, Loots MAM, van der Wal AC, Bos JD, Causes, investigation and treatment of leg ulceration. BRIT J DERMATOL 2003;148 (3):388-401 [PubMed]
Piskin G, Heydendael VMR, de Rie MA, Bos JD, Teunissen MBM, Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ. ARCH DERMATOL RES 2003;294 (12):559-562 [PubMed]
Piskin G, Koomen CW, Picavet D, Bos JD, Teunissen MBM, Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. EXP DERMATOL 2003;12 (2):172-180 [PubMed]
Piskin G, Sylva-Steenland RMR, Bos JD, Behandeling met smalspectrum-UVB vermindert expressie van IFN-gamma in dermale T-cellen in lesionale psoriatische huid. NED TIJDSCHR DERMATOL VENEREOL 2003;13:67
Piskin G, Tursen U, Bos JD, Teunissen MBM, IL-4 expression by neutrophils in psoriasis lesional skin upon high-dose UVB exposure. DERMATOLOGY 2003;207 (1):51-53 [PubMed]
van den Berg P, Bos JD, Psoriasis. NED TIJDSCHR GENEESKD 2003;6 (4):68-69
van Leent EJM, Bos JD. Atopic dermatitis in: European Handbook of Dermatological Treatments (2nd ed.). Berlin: Springer; 2003., p. 54-62
Bos JD, Atopiform dermatitis. BRIT J DERMATOL 2002;147 (3):426-429 [PubMed]
Bos JD. Système immunitaire cutané (SIC) in: Thivolet J, Nicolas JF, editors. Immunologie cutanée. Paris: John Libbey Eurotext; 2002., p. 6-11
Bos JD, Topical tacrolimus and pimecrolimus are not associated with skin atrophy. BRIT J DERMATOL 2002;146 (2):342 [PubMed]
de Korte J, Mombers FMC, Sprangers MAG, Bos JD, The suitability of quality-of-life questionnaires for psoriasis research - A systematic literature review. ARCH DERMATOL 2002;138 (9):1221-1227 [PubMed]
Di Nuzzo S, Sylva-Steenland RMR, Koomen CW, Nakagawa S, van Breemen M, de Rie MA, Das PK, Bos JD, Teunissen MBM, UVB irradiation of normal human skin favors the development of type-2 T-cells in vivo and in primary dermal cell cultures. PHOTOCHEM PHOTOBIOL 2002;76 (3):301-309 [PubMed]
Gottlieb AB, Bos JD, Recombinantly engineered human proteins: Transforming the treatment of psoriasis. CLIN IMMUNOL 2002;105 (2):105-116 [PubMed]
Heydendael VMR, Spuls PI, ten Berge IJM, Opmeer BC, Bos JD, de Rie MA, Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. BRIT J DERMATOL 2002;147 (1):122-129 [PubMed]
Kozel MMA, Moein MCA, Mekkes JR, Meinardi MMHM, Bossuyt PMM, Bos JD, Evaluation of a clinical guideline for the diagnoses of physical and chronic urticaria and angioedema. ACTA DERM-VENEREOL 2002;82 (4):270-274 [PubMed]
Kraan MC, van Kuijk AWR, Dinant HJ, Goedkoop AY, Smeets TJM, de Rie MA, Dijkmans BAC, Vaishnaw AK, Bos JD, Tak PP, Alefacept treatment in psoriatic arthritis - Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. ARTHRITIS RHEUM-US 2002;46 (10):2776-2784 [PubMed]
Loot MAM, Kenter SB, Au FL, van Galen WJM, Middelkoop E, Bos JD, Mekkes JR, Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. EUR J CELL BIOL 2002;81 (3):153-160 [PubMed]
Loots MAM. Wound healing in diabetic ulcers. S.l.: s.n.; 2002. 188p. ISBN 90-9015484-1 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Mekkes JR, Middelkoop E)
Spuls PI. Clinical evidence for the treatment of moderate to severe psoriasis. S.l.: s.n.; 2002. 225p. ISBN 90-9015946-0 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD, Bossuyt PMM; copromotor(s): Witkamp L)
Szabó AK, Bos JD, Das PK, Hyperproliferation of normally quiescent keratinocytes in non-lesional psoriatic skin due to high calcium concentration (an organotypic culture model). ACTA MICROBIOL IMMUNOL HUNG 2002;49 (1):129-140 [PubMed]
Teunissen MBM, Piskin G, Di Nuzzo S, Sylva-Steenland RMR, de Rie MA, Bos JD, Ultraviolet B radiation induces a transient appearance of IL-4(+) neutrophils, which support the development of Th2 responses. J IMMUNOL 2002;168 (8):3732-3739 [PubMed]
van Leent EJM. Development of new treatment modalities for atopic dermatitis. S.l.: s.n.; 2002. 212p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Bos JD; copromotor(s): Sillevis Smitt JH)
van Leent EJM, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD, Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. DERMATOLOGY 2002;204 (1):63-68 [PubMed]
Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y, Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. PEDIATRICS 2002;110 (1 Part 1):e2 [PubMed]
Bos JD. Topical skin immune system rseponse modifiers in: Thomson AW, editor. Therapeutic immunosuppression. Dordrecht/Boston/London: Kluwer Academic Publishers; 2001., p. 323-332
Bos JD, Pasch MC, Asghar SS, Defensins and complement systems from the perspective of skin immunity and autoimmunity. CLIN DERMATOL 2001;19 (5):563-572 [PubMed]
Kammeyer A, Eggelte TA, Overmars H, Bootsma A, Bos JD, Teunissen MB, Oxidative breakdown and conversion of urocanic acid isomers by hydroxyl radical generating systems. BBA-GEN SUBJECTS 2001;1526 (3):277-285 [PubMed]
Kozel MM, Mekkes JR, Bossuyt PM, Bos JD, Natural course of physical and chronic urticaria and angioedema in 220 patients. J AM ACAD DERMATOL 2001;45 (3):387-391 [PubMed]
Luger T, van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schoepf E, Thestrup-Pedersen K, van der Valk PG, Bos JD, SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. BRIT J DERMATOL 2001;144 (4):788-794 [PubMed]
Nakagawa S, Bos JD, Role of Langerhans cells in the skin. What's new?. J EUR ACAD DERMATOL 2001;15 (5):399-401 [PubMed]
Bos JD, SDZ ASM 981: A Viewpoint by Jan D. Bos. BIODRUGS 2000;14 (6):417-418 [PubMed]
Bos JD, Meinardi MM, The 500 Dalton rule for the skin penetration of chemical compounds and drugs. EXP DERMATOL 2000;9 (3):165-169 [PubMed]
de Rie MA, Bos JD, Photochemotherapy for systemic and localized scleroderma. J AM ACAD DERMATOL 2000;43 (4):725-726 [PubMed]
de Rie MA, Di Nuzzo S, Brands S, Hansen AB, Bos JD, Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema. BRIT J DERMATOL 2000;142 (6):1160-1165 [PubMed]
de Vries HJ, Enomoto DN, van Marle J, van Zuijlen PP, Mekkes JR, Bos JD, Dermal organization in scleroderma: the fast Fourier transform and the laser scatter method objectify fibrosis in nonlesional as well as lesional skin. LAB INVEST 2000;80 (8):1281-1289 [PubMed]
Di Nuzzo S, Sylva-Steenland RM, Koomen CW, de Rie MA, Das PK, Bos JD, Teunissen MB, Exposure to UVB induces accumulation of LFA-1+ T cells and enhanced expression of the chemokine psoriasin in normal human skin. PHOTOCHEM PHOTOBIOL 2000;72 (3):374-382 [PubMed]
Njoo MD, Bos JD, Westerhof W, Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J AM ACAD DERMATOL 2000;42 (2 Part 1):245-253 [PubMed]
Pasch MC, van den Bosch NH, Daha MR, Bos JD, Asghar SS, Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. J INVEST DERMATOL 2000;114 (1):78-82 [PubMed]
Bos JD, Reappraisal of dermatoses of pregnancy. LANCET 1999;354 (9185):1140 [PubMed]
Bos JD, de Rie MA, The pathogenesis of psoriasis: immunological facts and speculations. IMMUNOL TODAY 1999;20 (1):40-46 [PubMed]
Brands S, Brakman M, Bos JD, de Rie MA, No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J AM ACAD DERMATOL 1999;41 (6):991-995 [PubMed]
Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema R, de Rie MA, Schellekens PT, ten Berge IJ, de Borgie CA, Bos JD, Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J AM ACAD DERMATOL 1999;41 (6):915-922 [PubMed]
Hamerlinck FF, Klatser PR, Walsh DS, Bos JD, Walsh GP, Faber WR, Serum neopterin as a marker for reactional states in leprosy. FEMS IMMUNOL MED MIC 1999;24 (4):405-409 [PubMed]
Kammeyer A, Eggelte TA, Bos JD, Teunissen MB, Urocanic acid isomers are good hydroxyl radical scavengers: a comparative study with structural analogues and with uric acid. BBA-GEN SUBJECTS 1999;1428 (1):117-120 [PubMed]
Loots MA, Lamme EN, Mekkes JR, Bos JD, Middelkoop E, Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. ARCH DERMATOL RES 1999;291 (2-3):93-99 [PubMed]
Mekkes JR, Kozel MM, Bossuyt PM, Bos JD, Een vragenlijst voor patiënten met chronische urticaria: gestructureerde anamnese als basis voor diagnostisch beleid. NED TIJDSCHR GENEESKD 1999;143 (34):1748-1749 [PubMed]
Nakagawa S, Koomen CW, Bos JD, Teunissen MB, Differential modulation of human epidermal Langerhans cell maturation by ultraviolet B radiation. J IMMUNOL 1999;163 (10):5192-5200 [PubMed]
Njoo MD, Das PK, Bos JD, Westerhof W, Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. ARCH DERMATOL 1999;135 (4):407-413 [PubMed]
Njoo MD, Westerhof W, Bos JD, Bossuyt PM, The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. ARCH DERMATOL 1999;135 (12):1514-1521 [PubMed]
Pasch MC, Bos JD, Daha MR, Asghar SS, Transforming growth factor-beta isoforms regulate the surface expression of membrane cofactor protein (CD46) and CD59 on human keratinocytes [corrected]. EUR J IMMUNOL 1999;29 (1):100-108 [PubMed]
Bos JD, van Leent EJ, Sillevis Smitt JH, The millennium criteria for the diagnosis of atopic dermatitis. EXP DERMATOL 1998;7 (4):132-138 [PubMed]
de Rie MA, Bos JD, Immunological aspects of psoriasis. NETH J MED 1998;53 (3):143-144 [PubMed]
de Rie MA, Out TA, Bos JD, Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation. DERMATOLOGY 1998;196 (4):412-417 [PubMed]
Di Nuzzo S, Sylva-Steenland RM, de Rie MA, Das PK, Bos JD, Teunissen MB, UVB radiation preferentially induces recruitment of memory CD4+ T cells in normal human skin: long-term effect after a single exposure. J INVEST DERMATOL 1998;110 (6):978-981 [PubMed]
Kozel MM, Mekkes JR, Bossuyt PM, Bos JD, The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. ARCH DERMATOL 1998;134 (12):1575-1580 [PubMed]
Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E, Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J INVEST DERMATOL 1998;111 (5):850-857 [PubMed]
Mekkes JR, Le Poole IC, Das PK, Bos JD, Westerhof W, Efficient debridement of necrotic wounds using proteolytic enzymes derived from Antarctic krill: a double-blind, placebo-controlled study in a standardized animal wound model. WOUND REPAIR REGEN 1998;6 (1):50-57 [PubMed]
Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM, Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. ARCH DERMATOL 1998;134 (12):1532-1540 [PubMed]
Njoo MD, Westerhof W, Bos JD, Bossuyt PM, A systematic review of autologous transplantation methods in vitiligo. ARCH DERMATOL 1998;134 (12):1543-1549 [PubMed]
Pasch M, Bos JD, Asghar SS, Activation of complement in psoriasis. CLIN EXP DERMATOL 1998;23 (4):189-190 [PubMed]
Pasch MC, Okada N, Bos JD, Asghar SS, Effects of UVB on the synthesis of complement proteins by keratinocytes. J INVEST DERMATOL 1998;111 (4):683-688 [PubMed]
Snijders A, van der Pouw Kraan TC, Engel M, Wormmeester J, Widjaja P, Zonneveld IM, Bos JD, Kapsenberg ML, Enhanced prostaglandin E2 production by monocytes in atopic dermatitis (AD) is not accompanied by enhanced production of IL-6, IL-10 or IL-12. CLIN EXP IMMUNOL 1998;111 (3):472-476 [PubMed]
Spuls PI, Bossuyt PM, van Everdingen JJ, Witkamp L, Bos JD, The development of practice guidelines for the treatment of severe plaque form psoriasis. ARCH DERMATOL 1998;134 (12):1591-1596 [PubMed]
Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD, Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J INVEST DERMATOL 1998;111 (4):645-649 [PubMed]
van Leent EJ, Gräber M, Thurston M, Wagenaar A, Spuls PI, Bos JD, Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. ARCH DERMATOL 1998;134 (7):805-809 [PubMed]
Venneker GT, van den Hoogen FH, van Meegen M, de Kok-Nazaruk M, Hulsmans RF, Boerbooms AM, de Waal LP, Bos JD, Asghar SS, Molecular heterogeneity of second and fourth components of complement and their genes in systemic sclerosis and association of HLA alleles A1, B8 and DR3 with limited and DR5 with diffuse systemic sclerosis. EXP CLIN IMMUNOGENET 1998;15 (2):90-99 [PubMed]
Venneker GT, Vodegel RM, Okada N, Westerhof W, Bos JD, Asghar SS, Relative contributions of decay accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 in the protection of melanocytes from homologous complement. IMMUNOBIOLOGY 1998;198 (4):476-484 [PubMed]
Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, Dubertret L, Bos JD, Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. ARCH DERMATOL 1998;134 (9):1101-1102 [PubMed]
Barna M, Bos JD, Kapsenberg ML, Snijdewint FG, Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. BRIT J DERMATOL 1997;136 (4):536-541 [PubMed]
Bos JD, The skin as an organ of immunity. CLIN EXP IMMUNOL 1997;107 (Suppl. 1):3-5 [PubMed]
Bos JD, de Rie MA, Immunologie in de medische praktijk. VII. Psoriasis. NED TIJDSCHR GENEESKD 1997;141 (48):2334-2338 [PubMed]
de Rie MA, Bos JD, Cyclosporine immunotherapy. CLIN DERMATOL 1997;15 (5):811-821 [PubMed]
Enomoto DN, Schellekens PT, Yong SL, ten Berge IJ, Mekkes JR, Bos JD, Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy. PHOTOCHEM PHOTOBIOL 1997;65 (1):177-180 [PubMed]
Kammeyer A, Pavel S, Asghar SS, Bos JD, Teunissen MB, Prolonged increase of cis-urocanic acid levels in human skin and urine after single total-body ultraviolet exposures. PHOTOCHEM PHOTOBIOL 1997;65 (3):593-598 [PubMed]
Kremer IB, Sylva-Steenland RM, Bos JD, Teunissen MB, Despite the presence of UVB-induced DNA damage, HLA-DR+ cells from ex vivo UVB-exposed human skin are able to migrate and show no impaired allostimulatory capacity. J INVEST DERMATOL 1997;109 (5):626-631 [PubMed]
Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S, A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. NEW ENGL J MED 1997;337 (12):816-821 [PubMed]
Spuls PI, Witkamp L, Bossuyt PM, Bos JD, A systematic review of five systemic treatments for severe psoriasis. BRIT J DERMATOL 1997;137 (6):943-949 [PubMed]
Teunissen MB, Koomen CW, Jansen J, de Waal Malefyt R, Schmitt E, van den Wijngaard RM, Das PK, Bos JD, In contrast to their murine counterparts, normal human keratinocytes and human epidermoid cell lines A431 and HaCaT fail to express IL-10 mRNA and protein. CLIN EXP IMMUNOL 1997;107 (1):213-223 [PubMed]
Zonneveld IM, Meinardi MM, Karlsmark T, Johansen UB, Kuiters GR, Hamminga L, Staberg B, van't Veen AJ, Bossuyt PM, van Niel JC, Bos JD, Ranitidine does not affect psoriasis: a multicenter, double-blind, placebo-controlled study. J AM ACAD DERMATOL 1997;36 (6 Part 1):932-934 [PubMed]
de Rie MA, Cairo I, van Lier RA, Bos JD, Expression of the T-cell activation antigens CD27 and CD28 in normal and psoriatic skin. CLIN EXP DERMATOL 1996;21 (2):104-111 [PubMed]
de Rie MA, Zonneveld IM, Witkamp L, van Lier RA, Out TA, Bos JD, Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. ACTA DERM-VENEREOL 1996;76 (5):357-360 [PubMed]
Di Nuzzo S, de Rie MA, van der Loos CM, Bos JD, Teunissen MB, Solar-simulated ultraviolet irradiation induces selective influx of CD4+ T lymphocytes in normal human skin. PHOTOCHEM PHOTOBIOL 1996;64 (6):988-993 [PubMed]
Enomoto DN, Mekkes JR, Bossuyt PM, Hoekzema R, Bos JD, Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma. J AM ACAD DERMATOL 1996;35 (3 Part 1):381-387 [PubMed]
Frank RG, Bos JD, van der Meulen FW, Sterenborg HJCM, Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. GENITOURIN MED 1996;72 (1):70-71 [PubMed]
Kammeyer A, Meinardi MM, Bos JD, Teunissen MB, cis-urocanic acid is not useful as an immunosuppressive agent in the treatment of human allergic contact dermatitis. ARCH DERMATOL RES 1996;288 (11):725-727 [PubMed]
Kapsenberg ML, Hilkens CM, Jansen HM, Bos JD, Snijders A, Wierenga EA, Production and modulation of T-cell cytokines in atopic allergy. INT ARCH ALLERGY IMM 1996;110 (2):107-113 [PubMed]
Kremer IB, Hilkens CM, Sylva-Steenland RM, Koomen CW, Kapsenberg ML, Bos JD, Teunissen MB, Reduced IL-12 production by monocytes upon ultraviolet-B irradiation selectively limits activation of T helper-1 cells. J IMMUNOL 1996;157 (5):1913-1918 [PubMed]
Pistoor FH, Rambukkana A, Kroezen M, Lepoittevin JP, Bos JD, Kapsenberg ML, Das PK, Novel predictive assay for contact allergens using human skin explant cultures. AM J PATHOL 1996;149 (1):337-343 [PubMed]
Rambukkana A, Pistoor FH, Bos JD, Kapsenberg ML, Das PK, Effects of contact allergens on human Langerhans cells in skin organ culture: migration, modulation of cell surface molecules, and early expression of interleukin-1 beta protein. LAB INVEST 1996;74 (2):422-436 [PubMed]
Venneker GT, van Meegen M, de Kok-Nazaruk M, Hulsmans RF, de Waall LP, Bos JD, Asghar SS, Incomplete functional deficiencies of the fourth (C4) and second (C2) components of complement in a patient with linear frontoparietal scleroderma and his family. Deficiencies determined by a gene not linked to human leukocyte antigen system. EXP CLIN IMMUNOGENET 1996;13 (2):104-111 [PubMed]
Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ, Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. ARCH DERMATOL 1996;132 (2):184-187 [PubMed]
Zonneveld IM, de Rie MA, Beljaards RC, van der Rhee HJ, Wuite J, Zeegelaar J, Bos JD, The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. BRIT J DERMATOL 1996;135 (Suppl. 48):15-20 [PubMed]
Boersma BR, Westerhof W, Bos JD, Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients. J AM ACAD DERMATOL 1995;33 (6):990-995 [PubMed]
de Rie MA, van Eendenburg JP, Versnick AC, Stolk LM, Bos JD, Westerhof W, A new psoralen-containing gel for topical PUVA therapy: development, and treatment results in patients with palmoplantar and plaque-type psoriasis, and hyperkeratotic eczema. BRIT J DERMATOL 1995;132 (6):964-969 [PubMed]
Hoekzema R, Hulsebosch HJ, Bos JD, Demodicidosis or rosacea: what did we treat?. BRIT J DERMATOL 1995;133 (2):294-299 [PubMed]
Kaliński P, Hilkens CM, Wierenga EA, van der Pouw-Kraan TC, van Lier RA, Bos JD, Kapsenberg ML, Snijdewint FG, Functional maturation of human naive T helper cells in the absence of accessory cells. Generation of IL-4-producing T helper cells does not require exogenous IL-4. J IMMUNOL 1995;154 (8):3753-3760 [PubMed]
Kammeyer A, Teunissen MB, Pavel S, de Rie MA, Bos JD, Photoisomerization spectrum of urocanic acid in human skin and in vitro: effects of simulated solar and artificial ultraviolet radiation. BRIT J DERMATOL 1995;132 (6):884-891 [PubMed]
Kozel MM, Mekkes JR, Bos JD, Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients. CLIN EXP DERMATOL 1995;20 (1):60-61 [PubMed]
Kremer IB, Bos JD, Teunissen BM, Reduced antigen-presenting function of human Epstein-Barr virus (EBV)-B cells and monocytes after UVB radiation is accompanied by decreased expression of B7, intercellular adhesion molecule-1 (ICAM-1) and LFA-3. CLIN EXP IMMUNOL 1995;101 (3):461-467 [PubMed]
Pistoor FH, Kapsenberg ML, Bos JD, Meinardi MM, von Blomberg ME, Scheper RJ, Cross-reactivity of human nickel-reactive T-lymphocyte clones with copper and palladium. J INVEST DERMATOL 1995;105 (1):92-95 [PubMed]
Rambukkana A, Bos JD, Irik D, Menko WJ, Kapsenberg ML, Das PK, In situ behavior of human Langerhans cells in skin organ culture. LAB INVEST 1995;73 (4):521-531 [PubMed]
Snijdewint FG, Kapsenberg ML, Wauben-Penris PJ, Bos JD, Corticosteroids class-dependently inhibit in vitro Th1- and Th2-type cytokine production. IMMUNOPHARMACOLOGY 1995;29 (2):93-101 [PubMed]
Spuls PI, Brakman M, Westerhof W, Bos JD, Treatment of generalized bullous pemphigoid with topical corticosteroids. ACTA DERM-VENEREOL 1995;75 (1):89 [PubMed]
Teunissen MB, Koomen CW, Bos JD, Intercellular adhesion molecule-3 (CD50) on human epidermal Langerhans cells participates in T-cell activation. J INVEST DERMATOL 1995;104 (6):995-998 [PubMed]
Bos JD, The skin immune system: lupus erythematosus as a paradigm. ARCH DERMATOL RES 1994;287 (1):23-27 [PubMed]
Das PK, de Boer OJ, Visser A, Verhagen CE, Bos JD, Pals ST, Differential expression of ICAM-1, E-selectin and VCAM-1 by endothelial cells in psoriasis and contact dermatitis. ACTA DERM-VENEREOL 1994;74 (Suppl 186):21-22 [PubMed]
de Boer OJ, Horst E, Pals ST, Bos JD, Das PK, Functional evidence that the HECA-452 antigen is involved in the adhesion of human neutrophils and lymphocytes to tumour necrosis factor-alpha-stimulated endothelial cells. IMMUNOLOGY 1994;81 (3):359-365 [PubMed]
de Boer OJ, van der Loos CM, Hamerlinck F, Bos JD, Das PK, Reappraisal of in situ immunophenotypic analysis of psoriasis skin: interaction of activated HLA-DR+ immunocompetent cells and endothelial cells is a major feature of psoriatic lesions. ARCH DERMATOL RES 1994;286 (2):87-96 [PubMed]
de Boer OJ, Wakelkamp IM, Pals ST, Claessen N, Bos JD, Das PK, Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. ARCH DERMATOL RES 1994;286 (6):304-311 [PubMed]
Dooms-Goossens A, Meinardi MM, Bos JD, Degreef H, Contact allergy to corticosteroids: the results of a two-centre study. BRIT J DERMATOL 1994;130 (1):42-47 [PubMed]
Teunissen MB, Rongen HA, Bos JD, Function of adhesion molecules lymphocyte function-associated antigen-3 and intercellular adhesion molecule-1 on human epidermal Langerhans cells in antigen-specific T cell activation. J IMMUNOL 1994;152 (7):3400-3409 [PubMed]
Venneker GT, Das PK, Meinardi MM, van Marle J, van Veen HA, Bos JD, Asghar SS, Glycosylphosphatidylinositol (GPI)-anchored membrane proteins are constitutively down-regulated in psoriatic skin. J PATHOL 1994;172 (2):189-197 [PubMed]
Venneker GT, Das PK, Naafs B, Tigges AJ, Bos JD, Asghar SS, Morphoea lesions are associated with aberrant expression of membrane cofactor protein and decay accelerating factor in vascular endothelium. BRIT J DERMATOL 1994;131 (2):237-242 [PubMed]
Venneker GT, van den Hoogen FH, Boerbooms AM, Bos JD, Asghar SS, Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage. LAB INVEST 1994;70 (6):830-835 [PubMed]
Bos JD, de Boer OJ, Tibosch E, Das PK, Pals ST, Skin-homing T lymphocytes: detection of cutaneous lymphocyte-associated antigen (CLA) by HECA-452 in normal human skin. ARCH DERMATOL RES 1993;285 (4):179-183 [PubMed]
Bos JD, Kapsenberg ML, The skin immune system: progress in cutaneous biology. IMMUNOL TODAY 1993;14 (2):75-78 [PubMed]
Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W, Review of the etiopathomechanism of vitiligo: a convergence theory. EXP DERMATOL 1993;2 (4):145-153 [PubMed]
Snijdewint FG, Kaliński P, Wierenga EA, Bos JD, Kapsenberg ML, Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J IMMUNOL 1993;150 (12):5321-5329 [PubMed]
Teunissen MB, Sylva-Steenland RM, Bos JD, Effect of low-dose ultraviolet-B radiation on the function of human T lymphocytes in vitro. CLIN EXP IMMUNOL 1993;94 (1):208-213 [PubMed]
van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML, Serum-IgE-facilitated allergen presentation in atopic disease. J IMMUNOL 1993;150 (8 Part 1):3643-3650 [PubMed]
Witkamp L, Velthuis PJ, Verhaegh ME, Hulsmans RF, Bossuyt PM, Bos JD, Meinardi MM, An open prospective clinical trial with systemic ranitidine in the treatment of psoriasis. J AM ACAD DERMATOL 1993;28 (5 Part 1):778-781 [PubMed]
Bos JD, Wierenga EA, Sillevis Smitt JH , van der Heijden FL, Kapsenberg ML, Immune dysregulation in atopic eczema. ARCH DERMATOL 1992;128 (11):1509-1512 [PubMed]
Kapsenberg ML, Bos JD, Wierenga EA, T cells in allergic responses to haptens and proteins. SPRINGER SEMIN IMMUN 1992;13 (3-4):303-314 [PubMed]
Kapsenberg ML, Jansen HM, Bos JD, Wierenga EA, Role of type 1 and type 2 T helper cells in allergic diseases. CURR OPIN IMMUNOL 1992;4 (6):788-793 [PubMed]
Kapsenberg ML, Wierenga EA, Stiekema FE, Tiggelman AM, Bos JD, Th1 lymphokine production profiles of nickel-specific CD4+T-lymphocyte clones from nickel contact allergic and non-allergic individuals. J INVEST DERMATOL 1992;98 (1):59-63 [PubMed]
Rambukkana A, Das PK, Krieg S, Young S, Le Poole IC, Bos JD, Mycobacterial 65,000 MW heat-shock protein shares a carboxy-terminal epitope with human epidermal cytokeratin 1/2. IMMUNOLOGY 1992;77 (2):267-276 [PubMed]
Sillevis Smitt JH , Weening RS, Krieg SR, Bos JD, The skin in severe combined immunodeficiency: a case with transient cutaneous presence of gamma/delta (TRC1+) T cells. BRIT J DERMATOL 1992;127 (3):281-285 [PubMed]
Venneker GT, Westerhof W, de Vries IJ, Drayer NM, Wolthers BG, de Waal LP, Bos JD, Asghar SS, Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo. J INVEST DERMATOL 1992;99 (6):853-858 [PubMed]
de Rie MA, Hamerlinck F, Bos JD, Neopterin, immune activation, and psoriasis. LANCET 1991;338 (8776):1208 [PubMed]
de Rie MA, Hamerlinck F, Hintzen RQ, Bos JD, van Lier RA, Quantitation of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis. ARCH DERMATOL RES 1991;283 (8):533-534 [PubMed]
de Rie MA, Meinardi MM, Bos JD, Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. ACTA DERM-VENEREOL 1991;71 (5):452-454 [PubMed]
Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM, Functional subsets of allergen-reactive human CD4+ T cells. IMMUNOL TODAY 1991;12 (11):392-395 [PubMed]
Nanninga PB, Ghanem GE, Lejeune FJ, Bos JD, Westerhof W, Evidence for alpha-MSH binding sites on human scalp hair follicles: preliminary results. PIGM CELL RES 1991;4 (4):193-198 [PubMed]
Teunissen MB, de Jager MH, Kapsenberg ML, Bos JD, Inhibitory effect of cyclosporin A on antigen and alloantigen presenting capacity of human epidermal Langerhans cells. BRIT J DERMATOL 1991;125 (4):309-316 [PubMed]
van der Heijden FL, Wierenga EA, Bos JD, Kapsenberg ML, High frequency of IL-4-producing CD4+ allergen-specific T lymphocytes in atopic dermatitis lesional skin. J INVEST DERMATOL 1991;97 (3):389-394 [PubMed]
Wierenga EA, Snoek M, Jansen HM, Bos JD, van Lier RA, Kapsenberg ML, Human atopen-specific types 1 and 2 T helper cell clones. J IMMUNOL 1991;147 (9):2942-2949 [PubMed]
Bos JD, Teunissen MB, Cairo I, Krieg SR, Kapsenberg ML, Das PK, Borst J, T-cell receptor gamma delta bearing cells in normal human skin. J INVEST DERMATOL 1990;94 (1):37-42 [PubMed]
de Rie MA, Meinardi MM, Bos JD, Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. BRIT J DERMATOL 1990;123 (3):347-353 [PubMed]
Meinardi MM, de Rie MA, Bos JD, Oral cyclosporin A in the treatment of psoriasis: an overview of studies performed in The Netherlands. BRIT J DERMATOL 1990;122 (Suppl. 36):27-31 [PubMed]
Meinardi MM, de Rie MA, Bos JD, Oral cyclosporin A is effective in clearing persistent pustulosis palmaris et plantaris. ACTA DERM-VENEREOL 1990;70 (1):77-79 [PubMed]
Meinardi MM, van Eendenburg JP, Oosting J, van Boxtel CJ, de Rie MA, Bos JD, Cyclosporin A levels in suction-blister fluid of patients with psoriasis treated systemically. BRIT J DERMATOL 1990;122 (5):671-676 [PubMed]
Sillevis Smitt JH , Bos JD, Weening RS, Krieg SR, Discoid lupus erythematosus-like skin changes in patients with autosomal recessive chronic granulomatous disease. ARCH DERMATOL 1990;126 (12):1656-1658 [PubMed]
Sillevis Smitt JH , Weening RS, Krieg SR, Bos JD, Discoid lupus erythematosus-like lesions in carriers of X-linked chronic granulomatous disease. BRIT J DERMATOL 1990;122 (5):643-650 [PubMed]
Teunissen MB, Wormmeester J, Krieg SR, Peters PJ, Vogels IM, Kapsenberg ML, Bos JD, Human epidermal Langerhans cells undergo profound morphologic and phenotypical changes during in vitro culture. J INVEST DERMATOL 1990;94 (2):166-173 [PubMed]
Wierenga EA, Snoek M, Bos JD, Jansen HM, Kapsenberg ML, Comparison of diversity and function of house dust mite-specific T lymphocyte clones from atopic and non-atopic donors. EUR J IMMUNOL 1990;20 (7):1519-1526 [PubMed]
Wierenga EA, Snoek M, de Groot C, Chrétien I, Bos JD, Jansen HM, Kapsenberg ML, Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients. J IMMUNOL 1990;144 (12):4651-4656 [PubMed]
Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML, Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. ARCH DERMATOL RES 1989;281 (1):24-30 [PubMed]
Bos JD, Meinardi MM, Two distinct squamous cell carcinomas in a psoriasis patient receiving low-dose cyclosporine maintenance treatment. J AM ACAD DERMATOL 1989;21 (6):1305-1306 [PubMed]
Bos JD, Meinardi MM, van Joost T, Heule F, Powles AV, Fry L, Use of cyclosporin in psoriasis. LANCET 1989;2 (8678-8679):1500-1502 [PubMed]
Kapsenberg ML, Stiekema FE, Kallan A, Bos JD, Roozemond RC, The restrictive role of sialic acid in antigen presentation to a subset of human peripheral CD4+ T lymphocytes that requires antigen-presenting dendritic cells. EUR J IMMUNOL 1989;19 (10):1829-1834 [PubMed]
Kuiters GR, Smitt JH, Cohen EB, Bos JD, Allergic contact dermatitis in children and young adults. ARCH DERMATOL 1989;125 (11):1531-1533 [PubMed]
Sillevis Smitt JH , Gons MH, Oorthuys JW, Krieg SR, Bos JD, The poikiloderma of Rothmund-Thomson syndrome: changes in Langerhans cell morphology and distribution. DERMATOLOGICA 1989;179 (4):187-190 [PubMed]
Timmenga EJ, Schoorl R, Bos JD, Klopper PJ, An improved model for tissue expansion and flap research in the rabbit. BRIT J PLAST SURG 1989;42 (3):301-305 [PubMed]
Westerhof W, Buehre Y, Pavel S, Bos JD, Das PK, Krieg SR, Siddiqui AH, Increased anthralin irritation response in vitiliginous skin. ARCH DERMATOL RES 1989;281 (1):52-56 [PubMed]
Bos JD, The pathomechanisms of psoriasis; the skin immune system and cyclosporin. BRIT J DERMATOL 1988;118 (2):141-155 [PubMed]
de Groot AC, Bruynzeel DP, Bos JD, van der Meeren HL, van Joost T, Jagtman BA, Weyland JW, The allergens in cosmetics. ARCH DERMATOL 1988;124 (10):1525-1529 [PubMed]
de Wit FS, de Groot AC, Weyland JW, Bos JD, An outbreak of contact dermatitis from toluenesulfonamide formaldehyde resin in a nail hardener. CONTACT DERMATITIS 1988;18 (5):280-283 [PubMed]
Heule F, Meinardi MM, van Joost T, Bos JD, Low-dose cyclosporine effective in severe psoriasis: a double-blind study. TRANSPL P 1988;20 (3 Suppl 4):32-41 [PubMed]
Kapsenberg ML, van der Pouw-Kraan T, Stiekema FE, Schootemeijer A, Bos JD, Direct and indirect nickel-specific stimulation of T lymphocytes from patients with allergic contact dermatitis to nickel. EUR J IMMUNOL 1988;18 (7):977-982 [PubMed]
Meinardi MM, Bos JD, Cyclosporine maintenance therapy in psoriasis. TRANSPL P 1988;20 (3 Suppl 4):42-49 [PubMed]
Teunissen MB, Wormmeester J, Kapsenberg ML, Bos JD, Enrichment of unlabeled human Langerhans cells from epidermal cell suspensions by discontinuous density gradient centrifugation. J INVEST DERMATOL 1988;91 (4):358-362 [PubMed]
van Joost T, Bos JD, Heule F, Meinardi MM, Low-dose cyclosporin A in severe psoriasis. A double-blind study. BRIT J DERMATOL 1988;118 (2):183-190 [PubMed]
Bos JD, Zonneveld I, Das PK, Krieg SR, van der Loos CM, Kapsenberg ML, The skin immune system (SIS): distribution and immunophenotype of lymphocyte subpopulations in normal human skin. J INVEST DERMATOL 1987;88 (5):569-573 [PubMed]
de Groot AC, Bos JD, Preservatives in the European standard series for epicutaneous testing. BRIT J DERMATOL 1987;116 (3):289-292 [PubMed]
de Groot AC, de Wit FS, Bos JD, Weyland JW, Contact allergy to cocamide DEA and lauramide DEA in shampoos. CONTACT DERMATITIS 1987;16 (2):117-118 [PubMed]
Kapsenberg ML, Res P, Bos JD, Schootemijer A, Teunissen MB, van Schooten W, Nickel-specific T lymphocyte clones derived from allergic nickel-contact dermatitis lesions in man: heterogeneity based on requirement of dendritic antigen-presenting cell subsets. EUR J IMMUNOL 1987;17 (6):861-865 [PubMed]
Meinardi MM, Westerhof W, Bos JD, Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. BRIT J DERMATOL 1987;116 (2):269-270 [PubMed]
Res P, Kapsenberg ML, Bos JD, Stiekema F, The crucial role of human dendritic antigen-presenting cell subsets in nickel-specific T-cell proliferation. J INVEST DERMATOL 1987;88 (5):550-554 [PubMed]
Bos JD, van Garderen ID, Krieg SR, Poulter LW, Different in situ distribution patterns of dendritic cells having Langerhans (T6+) and interdigitating (RFD1+) cell immunophenotype in psoriasis, atopic dermatitis, and other inflammatory dermatoses. J INVEST DERMATOL 1986;87 (3):358-361 [PubMed]
de Groot AC, Bos JD, Jagtman BA, Bruynzeel DP, van Joost T, Weyland JW, Contact allergy to preservatives--II. CONTACT DERMATITIS 1986;15 (4):218-222 [PubMed]
de Groot AC, Weyland JW, Bos JD, Jagtman BA, Contact allergy to preservatives (I). CONTACT DERMATITIS 1986;14 (2):120-122 [PubMed]
Mekkes JR, van der Schaar WW, Bos JD, Anamnese en diagnostiek van chronische urticaria. NED TIJDSCHR GENEESKD 1986;130 (40):1801-1805 [PubMed]
Sillevis Smitt JH , Bos JD, Hulsebosch HJ, Krieg SR, In situ immunophenotyping of antigen presenting cells and T cell subsets in atopic dermatitis. CLIN EXP DERMATOL 1986;11 (2):159-168 [PubMed]
Westerhof W, Groot I, Krieg SR, Bos JD, Cormane RH, Langerhans' cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. ACTA DERM-VENEREOL 1986;66 (3):259-262 [PubMed]
Bos JD, Huisman PM, Krieg SR, Faber WR, Pityriasis rosea (Gibert): abnormal distribution pattern of antigen presenting cells in situ. ACTA DERM-VENEREOL 1985;65 (2):132-137 [PubMed]
Bos JD, Jansen FC, Timmer JG, Allergic contact dermatitis to amyl nitrite ('poppers'). CONTACT DERMATITIS 1985;12 (2):109 [PubMed]
Bos JD, Krieg SR, Psoriasis infiltrating cell immunophenotype: changes induced by PUVA or corticosteroid treatment in T-cell subsets, Langerhans' cells and interdigitating cells. ACTA DERM-VENEREOL 1985;65 (5):390-397 [PubMed]
Bos JD, A new approach to contact allergenicity screening. MED HYPOTHESES 1984;15 (2):103-108 [PubMed]
Bos JD, Sillevis Smitt JH , Krieg SR, Bakker PM, Vos GD, van Zaane DJ, Acute disseminated histiocytosis-X: in situ immunophenotyping with monoclonal antibodies. J CUTAN PATHOL 1984;11 (1):59-64 [PubMed]
de Groot AC, Bos JD, Liem DH, Contact allergy to bornelone. CONTACT DERMATITIS 1984;10 (1):45-46 [PubMed]
Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH, Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. ARCH DERMATOL RES 1983;275 (3):181-189 [PubMed]
Faber WR, Bos JD, Rietra PJ, Fass H, van Eijk RV, Treponemicidal levels of amoxicillin in cerebrospinal fluid after oral administration. SEX TRANSM DIS 1983;10 (3):148-150 [PubMed]
Westerhof W, Bos JD, Trigeminal trophic syndrome: a successful treatment with transcutaneous electrical stimulation. BRIT J DERMATOL 1983;108 (5):601-604 [PubMed]
Key publications

Bos JD, Brenninkmeijer EEA, Schram ME, Middelkamp-Hup MA, Spuls PI, Smitt JHS, Atopic eczema or atopiform dermatitis. EXP DERMATOL 2010;19 (4):325-331 [PubMed]
de Groot M, Teunissen MBM, Picavet DI, de Rie MA, Bos JD, Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. EXP DERMATOL 2010;19 (8):754-756 [PubMed]
Kezic S, Kammeyer A, Calkoen F, Fluhr JW, Bos JD, Natural moisturizing factor components in the stratum corneum as biomarkers of filaggrin genotype: evaluation of minimally invasive methods. BRIT J DERMATOL 2009;161 (5):1098-1104 [PubMed]
Brenninkmeijer EEA, Spuls PI, Legierse CM, Lindeboom R, Sillevis Smitt JH, Bos JD, Clinical differences between atopic and atopiform dermatitis. J AM ACAD DERMATOL 2008;58 (3):407-414 [PubMed]
Bos JD, Psoriasis, innate immunity, and gene pools. J AM ACAD DERMATOL 2007;56 (3):468-471 [PubMed]


All Publications

Research programmes

Prof. dr. J.D. Bos (IMMUNODERMATOLOGY)

Faculty
Prof. dr. J.D. Bos
J. de Korte MA PhD
Dr. E.J.M. van Leent MD
Dr. J.R. Mekkes MD
Dr. M.A. Middelkamp Hup MD PhD
Dr. J.H. Sillevis Smitt MD PhD
Prof. H.J.C. de Vries MD PhD (STI Outpatient Clinic, Public Health Service (GGD) Amsterdam and Centre for Infectious Diseases, (CIB/RIVM) Bilthoven, the Netherlands)

PhD Students
Drs. K. Szegedi MD

Other research related activities
  • None reported
Current research funding
  • None reported